research use only

Sovleplenib Syk inhibitor

Name: Sovleplenib
Brand: Selleck Chemicals
SKU: E4580
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.E4580

Sovleplenib (HMPL-523) is a highly potent and selective SYK inhibitor with IC50 of 0.025 μM, that exhibits anti-tumor activities in vitro and in vivo. This compound exhibits synergistic activities in combination with BTK, PI3Kδ, and Bcl2 family inhibitors in killing human-diffused large B cell lymphoma (DLBCL).

Chemical Structure

Molecular Weight: 482.60

Jump to

Quality Control

Batch: Purity: 99.80%

99.80

Related Targets	EGFR VEGFR PDGFR FGFR c-Met Src MEK CSF-1R FLT3 HER2
Other Syk Products	R406 R406 (free base) PRT062607 (P505-15) HCl Entospletinib (GS-9973) Piceatannol BAY 61-3606 dihydrochloride PRT-060318 2HCl TAK-659 Hydrochloride RO9021 R112

Solubility

In vitro
Batch:

DMSO : 12 mg/mL (24.86 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.700mg/ml (1.45mM)	Taking the 1 mL working solution as an example, add 50 μL of 14 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.250mg/ml (0.52mM)	Taking the 1 mL working solution as an example, add 50 μL of 5 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	482.60	Formula	C₂₄H₃₀N₆O₃S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	1415792-84-5	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Mechanism of Action

Targets/IC₅₀/Ki	Syk 0.025 μM
References	[1] https://ashpublications.org/blood/article/128/22/3970/114272/HMPL-523-a-Novel-SYK-Inhibitor-Showed-Anti-Tumor

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06291415	Recruiting	Immune Thrombocytopenia\|Blood Platelet Disorder\|Hematologic Diseases\|Purpura Thrombocytopenic\|Purpura\|Blood Coagulation Disorder\|Thrombotic Microangiopathies\|Hemorrhagic Disorders\|Autoimmune Diseases\|Immune System Diseases\|Hemorrhage\|Pathologic Processes\|Skin Manifestations\|Thrombocytopenia\|Purpura Thrombocytopenic Idiopathic\|Primary Immune Thrombocytopenia\|ITP - Immune Thrombocytopenia	Hutchmed	April 2 2024	Phase 1
NCT05720767	Completed	Relapsed or Refractory Lymphoma	Hutchmed	November 4 2022	Phase 1
NCT05571787	Completed	Relapsed or Refractory Lymphoma	Hutchmed	July 13 2022	Phase 1
NCT05318820	Completed	Healthy Subject	Hutchison Medipharma Limited\|Hutchmed	June 1 2022	Early Phase 1
NCT03483948	Terminated	Acute Myeloid Leukemia	Hutchison Medipharma Limited\|Hutchmed	October 9 2018	Phase 1
NCT02105129	Completed	Rheumatoid Arthritis (RA)	Hutchison Medipharma Limited\|Hutchmed	May 2014	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):